Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: A case report
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Rationale: Dumping syndrome is a frequent and potentially severe complication after gastric surgery. Beinaglutide, a recombinant human glucagon-like peptide-1 (GLP-1) which shares 100% homology with human GLP-1(7-36), has never been reported in the treatment of dumping syndrome before. Patient concerns: The patient had undergone distal gastrectomy for gastric signet ring cell carcinoma 16 months ago. He presented with symptoms of paroxysmal palpitation, sweating, and dizziness for 4 months. Diagnosis: He was diagnosed with late dumping syndrome. Interventions and outcomes: The patient was treated with dietary changes and acarbose for 4 months before admitted to our hospital. The treatment with dietary changes and acarbose did not prevent postprandial hyperinsulinemia and hypoglycemia according to the 75 g oral glucose tolerance test (OGTT) and continuous glucose monitoring (CGM) on admission. Therefore, the patient was treated with beinaglutide 0.1 mg before breakfast and lunch instead of acarbose. After the treatment of beinaglutide for 1 month, OGTT showed a reduction in postprandial hyperinsulinemia compared with before starting treatment, and the time in the range of 3.9 to 10 mmol/L became 100% in CGM. No side effect was observed in this patient during beinaglutide treatment. Lessons: These findings suggest that beinaglutide may be effective for treating post-gastrectomy late dumping syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Beinaglutide, a recombinant human GLP-1 (rhGLP-1) polypeptide, exhibits a remarkable resemblance to human GLP-1(7-36), with nearly 100% homology.120”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682 · cited 1×
“Accelerated gastric emptying plays an important role in the pathogenesis of late dumping syndrome after gastric surgery, it gives rise to a larger and earlier increase in plasma glucose, insulin, GLP-1, and GIP concentrations, and thus to reactive hypoglycemia.([3,8]) GLP-1RAs can reduce gastric emptying, which leads…”
Backgroundvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“GLP-1RAs can reduce gastric emptying, which leads to the reduction of hunger and food consumption in patients with type 2 diabetes or obesity.([9]) In patients with dumping syndrome, GLP-1RAs were also thought to have a therapeutic effect by inhibiting gastric emptying.”
BackgroundMechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433 · cited 1×
“The patient showed a weak response of cortisol, IGF-1, and glucagon to hypoglycemia at baseline, which may attribute to recurrent hypoglycemia.([13]) After 1-month beinaglutide treatment, the glucagon levels were not suppressed.”
BackgroundHare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276 · cited 1×
“Although glucagon-like peptide-1 receptor agonists (GLP1RAs) are reported as a treatment of glucose lowering by the inhibition of glucagon secretion and promotion of insulin secretion in patients with type 2 diabetes,([2]) and one of the underlying causes of late dumping syndrome is thought to be the postoperatively e…”
BackgroundLarge-Scale Investigation into Dumping Syndrome after Gastrectomy for Gastric Cancer
Mine, S., Sano, T., Tsutsumi, K., Murakami, Y., Ehara, K., Saka, M., Hara, K., Fukagawa, T., Udagawa, H., & Katai, H. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2010.07.003 · Cited by 106 · cited 1×
“Dumping syndrome is a frequent and potentially severe complication after gastric surgery.([1]) Late dumping syndrome is character-”
BackgroundAbrahamsson, N., Engström, B. E., Sundbom, M., & Karlsson, F. A. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0504 · Cited by 99 · cited 3×
“Exenatide, another GLP-1RA, shares less homology with human GLP-1 than liraglutide, was also used in one case of dumping syndrome.([7]) Beinaglutide, a new recombinant human GLP-1, shares 100% homology with human GLP-1(7-36).”
BackgroundInfluentialDirksen, C., Bojsen-Møller, K. N., Jørgensen, N. B., Jacobsen, S. H., Kristiansen, V. B., Naver, L., Hansen, D. L., Worm, D., Holst, J. J., & Madsbad, S. (2013) · Diabetologia · doi:10.1007/s00125-013-3055-1 · Cited by 98 · cited 1×
“Although glucagon-like peptide-1 receptor agonists (GLP1RAs) are reported as a treatment of glucose lowering by the inhibition of glucagon secretion and promotion of insulin secretion in patients with type 2 diabetes,([2]) and one of the underlying causes of late dumping syndrome is thought to be the postoperatively e…”
BackgroundØhrstrøm, C. C., Worm, D., Højager, A., Andersen, D., Holst, J. J., Kielgast, U. L., & Hansen, D. L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13796 · Cited by 72
Zhang, Y. L., Zhou, C., Li, X. F., Yang, M. N., Tao, L., Zheng, X. Y., & Jia, Y. S. (2019) · Obesity Science & Practice · doi:10.1002/osp4.342 · Cited by 49
Wu, S., Gao, L., Cipriani, A., Huang, Y., Yang, Z., Yang, J., Yu, S., Zhang, Y., Chai, S., Zhang, Z., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13613 · Cited by 48
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“120 This innovative compound demonstrates dose-dependent ef fi cacy in regulating glycemic control, suppressing appetite, delaying gastric emptying, and facilitating weight reduction.”
BackgroundGLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“The researcher believes that it may be related to the patient’s habit of excessive intake (44).”
BackgroundLlewellyn, D. C., Logan Ellis, H., Aylwin, S. J. B., Oštarijaš, E., Green, S., Sheridan, W., Chew, N. W. S., le Roux, C. W., Miras, A. D., Patel, A. G., et al. (2023) · Obesity · doi:10.1002/oby.23600 · Cited by 54
“[53] gave beinaglutide for 1 month and saw symptoms completely resolve.”
BackgroundInfluentialMasclee, G. M. C., & Masclee, A. (2023) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s392265 · Cited by 39
“…use of GLP-1RAs has also been described in individual cases: a patient with postsurgical late dumping syndrome symptoms after Toupet fundoplication (liraglutide) 14 and a patient after distal gastrectomy (beinaglutide) 15 by reducing symptomatic postprandial hyperinsulinemic hypoglycemic events.”
BackgroundKounatidis, D. C., Vallianou, N. G., Tsilingiris, D., Christodoulatos, G. S., Geladari, E. V., Stratigou, T., Karampela, Ι., & Dalamaga, Μ. (2022) · Current Nutrition Reports · doi:10.1007/s13668-022-00433-0 · Cited by 33
Metadata
- Authors
- Ding, B., Hu, Y., Yuan, L., Yan, R.-N., & Ma, J.-H.
- Affiliations
- Nanjing First Hospital (CN)
- ORCID
- Ding, Bo
- Venue
- Medicine
- Published
- 2021-05-28
- Volume
- 100
- Issue
- 21
- Pages
- e26086
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC8154494
- OpenAlex
- W3165541953
- Cited by
- 13
- References
- 14
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 1
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- late dumping syndrome, postgastrectomy complications, distal gastrectomy, GLP-1 receptor agonists, gastric signet ring cell carcinoma, postprandial hyperinsulinemia, hypoglycemia, acarbose, continuous glucose monitoring, dietary management
- MeSH terms
- Blood Glucose, Dumping Syndrome, Gastrectomy, Glucose Tolerance Test, Humans, Hyperinsulinism, Hypoglycemia, Male, Middle Aged, Peptide Fragments, Recombinant Proteins, Stomach Neoplasms, Treatment Outcome, Carcinoma, Signet Ring Cell, Postprandial Period, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: A case report. https://app.cochat.ai/papers/10.1097/md.0000000000026086
- The paper
- Ding, B., Hu, Y., Yuan, L., Yan, R.-N., & Ma, J.-H. (2021). Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: A case report. Medicine. https://doi.org/10.1097/md.0000000000026086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.